New York State Common Retirement Fund decreased its position in Accuray Incorporated (NASDAQ:ARAY) by 30.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,100 shares of the medical equipment provider’s stock after selling 31,721 shares during the quarter. New York State Common Retirement Fund owned approximately 0.09% of Accuray worth $342,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ARAY. Goldman Sachs Group Inc. raised its position in shares of Accuray by 116.3% in the first quarter. Goldman Sachs Group Inc. now owns 30,173 shares of the medical equipment provider’s stock valued at $143,000 after purchasing an additional 16,223 shares during the period. American International Group Inc. raised its position in shares of Accuray by 7.1% in the first quarter. American International Group Inc. now owns 49,098 shares of the medical equipment provider’s stock valued at $233,000 after purchasing an additional 3,256 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Accuray by 10.8% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,675 shares of the medical equipment provider’s stock valued at $264,000 after purchasing an additional 5,407 shares during the period. Wells Fargo & Company MN raised its position in shares of Accuray by 1.5% in the second quarter. Wells Fargo & Company MN now owns 62,059 shares of the medical equipment provider’s stock valued at $295,000 after purchasing an additional 936 shares during the period. Finally, SG Americas Securities LLC raised its position in shares of Accuray by 10.6% in the second quarter. SG Americas Securities LLC now owns 71,295 shares of the medical equipment provider’s stock valued at $339,000 after purchasing an additional 6,824 shares during the period. 75.47% of the stock is currently owned by institutional investors.

ARAY has been the topic of several research analyst reports. Jefferies Group LLC lowered their price objective on shares of Accuray from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 23rd. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Tuesday, October 24th. Cowen and Company restated a “buy” rating and issued a $9.00 price objective on shares of Accuray in a research note on Friday, October 27th. BTIG Research restated a “hold” rating on shares of Accuray in a research note on Thursday, August 24th. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $5.00 price objective on shares of Accuray in a research note on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $6.29.

In other Accuray news, COO Kelly Londy sold 99,136 shares of Accuray stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $4.24, for a total transaction of $420,336.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.90% of the stock is owned by insiders.

Shares of Accuray Incorporated (NASDAQ:ARAY) opened at $4.80 on Friday. The company has a debt-to-equity ratio of 2.44, a quick ratio of 0.92 and a current ratio of 1.48. Accuray Incorporated has a 52 week low of $3.60 and a 52 week high of $6.00.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Tuesday, October 24th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. Accuray had a negative net margin of 7.49% and a negative return on equity of 55.18%. The business had revenue of $91.00 million for the quarter, compared to the consensus estimate of $88.26 million. During the same quarter last year, the company posted ($0.12) earnings per share. Accuray’s quarterly revenue was up 5.2% on a year-over-year basis. sell-side analysts expect that Accuray Incorporated will post -0.18 EPS for the current year.

WARNING: “Accuray Incorporated (ARAY) Stake Lowered by New York State Common Retirement Fund” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://theolympiareport.com/2017/11/18/accuray-incorporated-aray-stake-lowered-by-new-york-state-common-retirement-fund.html.

Accuray Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.